Remove 2021 Remove Competition Remove Food and Drug Administration Remove Patients
article thumbnail

Can we get healthcare right?

World of DTC Marketing

Patients on Medicare who don’t qualify for low-income subsidies could see out-of-pocket costs for the drug of over $12,000. Isn’t it time for Congress to finally pass legislation that helps patients? These hospitals spent $116 million on federal lobbying in 2021. Innovation and Competition Act.

article thumbnail

FDA approves long-acting injectable for schizophrenia and bipolar disorder

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Rykindo ® (risperidone) for extended-release injectable suspension. The drug is indicated as a bi-weekly treatment for schizophrenia and as monotherapy or as adjunctive therapy to lithium or valproate for bipolar I disorder in adults.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lupkynis approved for the treatment of LN in the EU and UK

Pharmaceutical Technology

Notably, Lupkynis is the first oral therapy approved by the US Food and Drug Administration (FDA) and EC for the treatment of active LN. Key opinion leaders (KOLs) interviewed by GlobalData believe this may have significant impact on patients as the less-invasive route of administration will be preferred by many.

article thumbnail

FDA sketches a path for patient-focused drug development

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has released the fourth and final chapter in a series of guidance documents designed to support patient-focused drug development. The agency suggests that CAT could be used to collect patient scores in clinical trials.

FDA 52
article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

digital health sector plummeted to $15 billion from more than $29 billion in 2021, according to Rock Health. billion in 2021. And in the first quarter of this year, the largest Series A ever in digital health ($203M) went into a company accelerating clinical trials and drug development. digital health at $17.7

Pharma 104
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars. Senate Bill 562 (S.

article thumbnail

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.